Results 101 to 110 of about 7,490 (233)

The X Factor in Immunity: Sex Differences Shaped by the X Chromosome

Immunological Reviews, Volume 338, Issue 1, March 2026.
ABSTRACT There are sex differences with immune responses where females exhibit stronger immune responses compared to males. Both sex hormones and sex chromosome differences between males and females contribute to the observed sex differences with innate and adaptive immune cell composition and function.
Katherine B. Radovanovic, Megan Wynalda, Montserrat C. Anguera   +2 more
wiley   +1 more source

Ibrutinib Displays Atrial-Specific Toxicity in Human Stem Cell-Derived Cardiomyocytes

Stem Cell Reports, 2019
Summary: Ibrutinib (IB) is an oral Bruton's tyrosine kinase (BTK) inhibitor that has demonstrated benefit in B cell cancers, but is associated with a dramatic increase in atrial fibrillation (AF).
Sanam Shafaattalab, Eric Lin, Effimia Christidi, Haojun Huang, Yulia Nartiss, Analucia Garcia, Jeehon Lee, Stephanie Protze, Gordon Keller, Liam Brunham, Glen F. Tibbits, Zachary Laksman   +11 more
doaj   +1 more source

Polymethoxylated N‐Carboranyl Isoquinolinones: A New Scaffold for ABCG2 Inhibitors

ChemMedChem, Volume 21, Issue 3, 12 February 2026.
Combinations of a boron‐based clusters (carborane) and polymethoxy group patterns are crucial to overcome ABCG2‐mediated multidrug resistance in cancer cells. (Created in BioRender. Kuhnert, L. (2025) https://BioRender.com/h4cnh5m). ABCG2‐mediated multidrug resistance (MDR) is a major challenge among chemotherapeutic treatments of colon, pancreatic ...
Lydia Kuhnert, Philipp Stockmann, Peter Lönnecke, Mara Anna Wolniewicz, Evamarie Hey‐Hawkins, Walther Honscha   +5 more
wiley   +1 more source

The Use of Ibrutinib in Refractory Chronic Lymphocytic Leukemia and in High-Risk Patients

Клиническая онкогематология, 2019
Despite advances in chemo-immunotherapy of chronic lymphocytic leukemia, a choice of therapy is a frequent challenge in patients with a refractory form of the disease, autoimmune hemolytic complications, and also in high-risk patients with cytogenetic ...
Nadezhda Viktorovna Kurkina, E. A. Repina, N. N. Mashnina   +2 more
doaj   +1 more source

Machine learning methods for predicting adverse drug events: A systematic review

British Journal of Clinical Pharmacology, Volume 92, Issue 2, Page 422-444, February 2026.
Abstract Predicting adverse drug events (ADEs) in outpatient settings is crucial for improving medication safety, identifying high‐risk patients and reducing health‐care costs. While traditional methods struggle with the complexity of health‐care data, machine learning (ML) models offer improved prediction capabilities; however, their effectiveness in ...
Niaz Chalabianloo, Fatemeh Ahmadi, Mohammad Ali Omrani, Sheikh S. Abdullah, Neda Rostamzadeh, Atefeh Jafari, Lujain Izzedin, Kamran Sedig, Flory T. Muanda   +8 more
wiley   +1 more source

Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib. [PDF]

, 2016
Signaling via the B cell receptor (BCR) plays an important role in the pathogenesis and progression of chronic lymphocytic leukemia (CLL). This is underscored by the clinical effectiveness of ibrutinib, an inhibitor of Bruton's tyrosine kinase (BTK) that
Chen, L, Chen, Y, Choi, MY, Cui, B, Kipps, TJ, Rassenti, LZ, Widhopf Ii, GF, Wu, Christina, Yu, J, Zhang, L   +9 more
core   +1 more source

Incidence, Prevalence, Survival and Mortality of Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma and Waldenström Macroglobulinaemia in Australia

Cancer Medicine, Volume 15, Issue 2, February 2026.
ABSTRACT Background Mature B‐cell neoplasms chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) and waldenström macroglobulinaemia (WM) are highly prevalent in older populations. Aims This study quantified the incidence, prevalence and relative survival/mortality rate in Australia for CLL/SS and WM and reported the past trends. Materials
Dieu Nguyen, Shalika Bohingamu Mudiyanselage, Dipti Talaulikar, Fei‐Li Zhao, Boxiong Tang, Mostafa Kamal, Lan Gao   +6 more
wiley   +1 more source

Role of Tyrosine Kinase Inhibitors in Indolent and Other Mature B-Cell Neoplasms

Biomarker Insights, 2015
Targeting tyrosine kinases represents a highly specific treatment approach for different malignancies. This also includes non-Hodgkin lymphoma since it is well known that these enzymes are frequently involved in the lymphomagenesis.
Nadine Kutsch, Reinhard Marks, Richard Ratei, Thomas K. Held, Martin Schmidt-Hieber   +4 more
doaj   +1 more source

Overcoming challenges in CAR‐T therapy for malignancies: Mechanisms and strategies

Clinical and Translational Discovery, Volume 6, Issue 1, February 2026.
Chimeric antigen receptor T (CAR‐T) cell therapy faces three major challenges: tumour‐intrinsic resistance mechanisms, limitations in CAR‐T cell efficacy and immunosuppressive tumour microenvironment (TME) effects. Emerging strategies address these hurdles through precision targeting enhancement, optimised CAR‐T cell persistence/functionality and TME ...
Yushan Huang, Jun Long, Changpeng Yang, Wang Lu, Husheng Mei, Wenbin Qian, Jing Yang, Aibin Liang   +7 more
wiley   +1 more source

Contribution of plasma cells and B cells to hidradenitis suppurativa pathogenesis

JCI Insight, 2020
Hidradenitis suppurativa (HS) is a debilitating chronic inflammatory skin disease characterized by chronic abscess formation and development of multiple draining sinus tracts in the groin, axillae, and perineum.
Johann E. Gudjonsson, Lam C. Tsoi, Feiyang Ma, Allison C. Billi, K.R. van Straalen, A.R.J.V. Vossen, H.H. van der Zee, Paul W. Harms, Rachael Wasikowski, Christine M. Yee, Syed M. Rizvi, Xianying Xing, Enze Xing, Olesya Plazyo, Chang Zeng, Matthew T. Patrick, Margaret M. Lowe, Richard E. Burney, Jeffrey H. Kozlow, Jill R. Cherry-Bukowiec, Yanyun Jiang, Joseph Kirma, Stephan Weidinger, Kelly C. Cushing, Michael D. Rosenblum, Celine Berthier, Amanda S. MacLeod, John J. Voorhees, Fei Wen, J. Michelle Kahlenberg, Emanual Maverakis, Robert L. Modlin, Errol P. Prens   +32 more
doaj   +1 more source